Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412105 | 0.91 | TRPV1 (0.46) | TRPV1FFAR1FFAR4USP2KDM4E | |
| SCHEMBL5395614 | 0.91 | LTB4R (0.41) | TRPV1POLBLTB4RLTB4R2USP2 | |
| SCHEMBL5392273 | 0.90 | TRPV1 (0.44) | TRPV1RAB9AFFAR1NPC1POLB | |
| SCHEMBL5409148 | 0.90 | TRPV1 (0.48) | TRPV1POLBALDH1A1 | |
| SCHEMBL5400596 | 0.88 | TRPV1 (0.48) | TRPV1FFAR1NOTUMALDH1A1 | |
| SCHEMBL5398696 | 0.88 | TRPV1 (0.47) | TRPV1POLBNOTUMKDM4E | |
| SCHEMBL5412150 | 0.87 | TBXAS1 (0.46) | TRPV1 | |
| SCHEMBL4926471 | 0.87 | POLB (0.45) | TRPV1POLBLTB4RLTB4R2LMNA | |
| SCHEMBL4930232 | 0.87 | POLB (0.41) | TRPV1POLBLMNAMAPK1NOTUM | |
| SCHEMBL5401132 | 0.86 | TRPV1 (0.51) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO.,LTD. | 2008-03-13 | — | — | US | disclosed |
| US-7300917-B2 | Remedy for chronic disease | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | TRPV1 1916/4885RAB9A 3132/4885FFAR1 65/4885 |
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | EDNRA, EDNRB, LPAR2 | TRPV1 2000/4885RAB9A 3164/4885FFAR1 143/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | TRPV1 2000/4885RAB9A 3164/4885FFAR1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.